14 April 2017 - Congressional hearings. Federal investigations. Consumer outrage.

In the wake of developments like these, many drug company executives are laying low. Their favoured business models, based on raising drug prices indiscriminately, are now seen as a liability; many pharmaceutical companies are curbing increases on their products and accepting that this once-lucrative jig may be up.

Not Arthur P. Bedrosian, chief executive of Lannett Company. A generic drug maker with roughly $600 million in net sales in fiscal 2016, Lannett continues to push prices skyward on some of its offerings. And those moves are noteworthy on two accounts: First, its drugs are all off patent, meaning they are no longer proprietary formulations and should sell at deep discounts. The other: Lannett is raising prices even as it faces an antitrust inquiry from the Justice Department and a drug-pricing investigation by Connecticut’s attorney general.

Read New York Times article